Company intelligence / Profile preview

Stromedix

Cambridge, Massachusetts, United Statesinvestors.biogen.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Stromedix developed innovative therapies targeting fibrosis and organ failure. Its lead compound, STX‑100, completed Phase 1 clinical trials with plans for Phase 2 in idiopathic pulmonary fibrosis and chronic allograft nephropathy. The FDA granted orphan drug designation to STX‑100 for both indications. The company was acquired by Biogen Idec in February 2012.

Therapeutic areas: OtherOncologyPulmonologyNephrology
Modalities: Monoclonal antibodies (mAbs)biologics
Industry: Biotech

Drug pipeline

1 asset

STX-100

Phase 2

Indications: Idiopathic pulmonary fibrosis

Partnerships

University of California San Francisco (UCSF) licensing agreement for pipeline expansioninvestors included Atlas Venture, New Leaf Venture Partners, Frazier Healthcare Ventures, Bessemer Venture Partners, Red Abbey Venture PartnersBiogen Idec was also an investor before acquiring the company

Beyond the preview

Go deeper on Stromedix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stromedix.

Explore the full profile